Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
12 déc. 2024 09h00 HE
|
Exagen Inc.
CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
14 nov. 2024 16h30 HE
|
Exagen Inc.
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus...
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
13 nov. 2024 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following...
Exagen Inc. Reports Third Quarter 2024 Results
12 nov. 2024 08h00 HE
|
Exagen Inc.
Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments CARLSBAD,...
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
29 oct. 2024 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024,...
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
21 oct. 2024 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College...
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
04 sept. 2024 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global...
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
05 août 2024 08h00 HE
|
Exagen Inc.
CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30,...
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
02 août 2024 09h00 HE
|
Exagen Inc.
CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th...
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
01 août 2024 09h00 HE
|
Exagen Inc.
CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of...